Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Subcutaneous enoxaparin is currently the gold standard for VTE chemoprophylaxis. However, the
efficacy of chemoprophylaxis with subcutaneous enoxaparin is affected by patient-level
factors, thus, resulting in VTE events despite guideline-compliant prophylaxis. A population
at particular risk is the growing number of patients who undergo autologous breast
reconstruction. Direct oral anticoagulants (DOAC) might be a less invasive, yet, more
efficacious mode of chemoprophylaxis in this patient population. Hence, the proposed work has
the potential to cause a paradigm shift in chemoprophylaxis guidelines in a large population
of patients undergoing plastic surgery.